FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2713-2715 June 24, 2004 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Neoptolemos, J. P. PubMed Citation

To the Editor: Neoptolemos et al. (March 18 issue)¹ report the results of a trial conducted by the European Study Group for Pancreatic Cancer (ESPAC-1), which showed a survival advantage for adjuvant chemotherapy, but a deleterious effect of chemoradiotherapy. We would like to emphasize the suboptimal nature of the radiotherapy delivered in this trial. The regimen of chemoradiotherapy used was taken from the Gastrointestinal Tumor Study Group (GITSG) trial,² which was reported in 1985 but conceived in the early 1970s. The use of a split-course technique prolongs the overall treatment time and is known to reduce the rate of local . . . [Full Text of this Article]

This article has been cited by other articles:

• Regine, W. F., Winter, K. A., Abrams, R. A., Safran, H., Hoffman, J. P., Konski, A., Benson, A. B., Macdonald, J. S., Kudrimoti, M. R., Fromm, M. L., Haddock, M. G., Schaefer, P., Willett, C. G., Rich, T. A. (2008). Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial. JAMA 299: 1019-1026 [Abstract] [Full Text]  
• Small, W. Jr, Berlin, J., Freedman, G. M., Lawrence, T., Talamonti, M. S., Mulcahy, M. F., Chakravarthy, A. B., Konski, A. A., Zalupski, M. M., Philip, P. A., Kinsella, T. J., Merchant, N. B., Hoffman, J. P., Benson, A. B., Nicol, S., Xu, R. M., Gill, J. F., McGinn, C. J. (2008). Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial. JCO 26: 942-947 [Abstract] [Full Text]